DeepMed Research

Tasly Pharmaceutical Group Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Public, Subsidiary

Established: 1998-04-30

Employees: 9.2K

Market Cap: -

Website: https://www.taslypharma.com

Clinical Trials

A Study of the Safety and Efficacy of Pimavanserin in Patients with Parkinson's Disease Psychosis

Phase 3

Recruiting

Conditions: Parkinson's Disease Psychosis

Interventions: Drug: pimavanserin tartrate
Drug: placebo

First Posted Date: 2023-10-05

Last Posted Date: 2025-01-09

Lead Sponsor: Tasly Pharmaceutical Group Co., Ltd

Target Recruit Count: 248

Registration Number: NCT06068465

Locations: 🇨🇳
Xuan Wu Hospital, Beijing, Beijing, China
🇨🇳
The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
🇨🇳
Huai'an Second People's Hospital, Huaian, Jiangsu, China

and more 24 locations

Efficacy and Safety of Jiuweihuaban Pill for Treating Plaque Psoriasis

Phase 2

Not yet recruiting

Conditions: Plaque Psoriasis

Interventions: Drug: low dose Jiuweihuaban Pill
Drug: high dose Jiuweihuaban Pill
Drug: Jiuweihuaban Pill placebo

First Posted Date: 2023-09-28

Last Posted Date: 2023-09-29

Lead Sponsor: Tasly Pharmaceutical Group Co., Ltd

Target Recruit Count: 180

Registration Number: NCT06058546

Locations: 🇨🇳
Beijing traditional Chinese medicine hospital affiliated to Capital Medical University, Beijing, China
🇨🇳
Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, China
🇨🇳
The First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, China

and more 9 locations

Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis)

Phase 2

Recruiting

Conditions: Diabetic Kidney Disease

Interventions: Drug: High dose Qishen Yiqi Dripping Pills 3 bags
Drug: Qishen Yiqi Dripping Pills placebo 3 bags
Drug: Low dose Qishen Yiqi Dripping Pills 3 bags

First Posted Date: 2023-08-23

Last Posted Date: 2024-03-13

Lead Sponsor: Tasly Pharmaceutical Group Co., Ltd

Target Recruit Count: 228

Registration Number: NCT06006689

Locations: 🇨🇳
Dongzhimen Hospital of Beijing University of Chinese Medicine, Beijing, Beijing, China
🇨🇳
Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, Beijing, China
🇨🇳
The Affiliated TCM Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

and more 13 locations

A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo

Phase 3

Recruiting

Conditions: Ankylosing Spondylitis

Interventions: Drug: a simulated agent of Jitongning tablets
Drug: Jitongning tablets

First Posted Date: 2023-08-21

Last Posted Date: 2024-11-21

Lead Sponsor: Tasly Pharmaceutical Group Co., Ltd

Target Recruit Count: 408

Registration Number: NCT06000956

Locations: 🇨🇳
Yunnan Province Hospital of Traditional Chinese Medicine, Kunming, Yunnan, China
🇨🇳
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, Beijing, China
🇨🇳
The First Hospital of Lanzhou University, Lanzhou, Gansu, China

and more 7 locations

A Study of the Safety,Tolerability,and Pharmacokinetics of Multiple-Ascending Dose JS1-1-01 in Healty Subjects.

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Placebo
Drug: JS1-1-01

First Posted Date: 2022-12-19

Last Posted Date: 2024-11-19

Lead Sponsor: Tasly Pharmaceutical Group Co., Ltd

Target Recruit Count: 48

Registration Number: NCT05656274

Locations: 🇨🇳
Shanghai Mental Health Center, Shanghai, China

HuHuangLianzonggan Capsule in Subjects With Nonalcoholic Steatohepatitis: a Phase 2 tRial(HHL-HEPAR)

Phase 2

Recruiting

Conditions: NASH

Interventions: Drug: HuHuangLianzonggan capsule
Drug: HuHuangLianzonggan capsule placebo

First Posted Date: 2022-12-01

Last Posted Date: 2024-08-29

Lead Sponsor: Tasly Pharmaceutical Group Co., Ltd

Target Recruit Count: 76

Registration Number: NCT05632861

Locations: 🇨🇳
Ningbo Huamei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang, China
🇨🇳
Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, China
🇨🇳
Taizhou Municipal Hospital, Taizhou, Zhejiang, China

and more 17 locations

Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart Failure

Phase 2

Completed

Conditions: Chronic Heart Failure With Reduced Ejection Fraction

Interventions: Drug: High dose QiShen YiQi Dripping Pills 3 bags
Drug: Low dose QiShen YiQi Dripping Pills 3 bags
Drug: QiShen YiQi Dripping Pills placebo 3 bags

First Posted Date: 2021-07-30

Last Posted Date: 2025-01-10

Lead Sponsor: Tasly Pharmaceutical Group Co., Ltd

Target Recruit Count: 228

Registration Number: NCT04983043

Locations: 🇨🇳
Hefei First People's Hospital, Hefei, Anhui, China
🇨🇳
The First Hospital of ANHUI University of Science & Technology, Huainan, Anhui, China
🇨🇳
Suzhou Municipal Hospital, Suzhou, Anhui, China

and more 20 locations

Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Preserved Ejection Fraction

Phase 2

Completed

Conditions: Chronic Heart Failure With Preserved Ejection Fraction

Interventions: Drug: Qishen Yiqi dripping pills 4 bags/time
Drug: Qishen Yiqi dripping pills placebo 4 bags/time
Drug: Qishen Yiqi dripping pills 2 bags/time + Qishen Yiqi dripping pills placebo 2 bags/time

First Posted Date: 2021-06-30

Last Posted Date: 2025-01-09

Lead Sponsor: Tasly Pharmaceutical Group Co., Ltd

Target Recruit Count: 225

Registration Number: NCT04944706

Locations: 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳
Beijing Hospital, Beijing, Beijing, China
🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

and more 13 locations

Efficacy and Safety of Changkang Granule in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

Phase 2

Conditions: Irritable Bowel Syndrome with Diarrhea

Interventions: Drug: Changkang Placebo Granule
Drug: Changkang Granule

First Posted Date: 2020-07-30

Last Posted Date: 2020-07-30

Lead Sponsor: Tasly Pharmaceutical Group Co., Ltd

Target Recruit Count: 240

Registration Number: NCT04492787

Locations: 🇨🇳
Xiyuan Hospital, China Academy of Traditional Chinese Medicine, Beijing, China
🇨🇳
Shengjing Hospital of China Medical University, Dalian, China
🇨🇳
Gansu Provincial Hospital of TCM, Gansu, China

and more 5 locations

A Phase Ⅱ Clinical Study of Sanhuangjingshimingwan in Wet( Neovascular)Age-related Macular Degeneration(wAMD) Subjects

Phase 2

Completed

Conditions: Age-related Macular Degeneration

Interventions: Drug: Sanhuangjingshimingwan
Drug: Sanhuangjingshimingwan Placebo

First Posted Date: 2020-07-27

Last Posted Date: 2022-11-25

Lead Sponsor: Tasly Pharmaceutical Group Co., Ltd

Target Recruit Count: 78

Registration Number: NCT04486963

Locations: 🇨🇳
Tianjin Medical University Eye Hospital, Tianjin, Tianjin, China
🇨🇳
Beijing Hospital, Beijing, Beijing, China
🇨🇳
Beijing Tongren Hospital, Beijing, Beijing, China

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy